Physician profile
Emad Khaleeli
NPI 1346273497
$2,501.67
in general payments reported to CMS, 2019-2025
27 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $214 · 2021: $284 · 2022: $502 · 2023: $456 · 2024: $359 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $248.40 | 2020-2025 | Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $247.37 | 2022-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $238.86 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $197.79 | 2020-2024 | |
| Pfizer INC. | $189.39 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $159.19 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.23 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $150.21 | 2020-2022 | |
| Amgen INC. | $146.01 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $101.54 | 2022-2023 | Verquvo |
| Abiomed | $96.17 | 2022-2023 | Impella |
| E.R. Squibb & Sons, L.L.C. | $68.25 | 2020-2022 | |
| Amarin Pharma, INC. | $66.05 | 2020-2021 | |
| Lilly USA, LLC | $58.83 | 2022-2025 | Mounjaro, Zepbound |
| Alnylam Pharmaceuticals INC. | $57.05 | 2022-2023 | Amvuttra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $42.67 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $39.17 | 2023 | Inpefa |
| Heartflow, INC. | $36.10 | 2022 | |
| Exact Sciences Corporation | $32.70 | 2024 | Cologuard Collection Kit |
| Kiniksa Pharmaceuticals, LTD. | $31.47 | 2023 | Arcalyst |
| Novo Nordisk INC | $22.70 | 2020 | |
| Biotronik INC. | $22.48 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.36 | 2022 | |
| Arbor Pharmaceuticals, INC. | $18.48 | 2019 | |
| Esperion Therapeutics, INC. | $18.07 | 2025 | Nexletol |
| Medicomp INC | $17.13 | 2020 | |
| Kestra Medical Technology Services, INC. | $17.00 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emad Khaleeli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.